China Takes Global Lead in Biomaterials International Standardization
China has achieved a landmark position in international biomaterials standardization, with two Chinese-led proposals for surgical implant standards officially approved for development on June 4, 2026. The proposals — Surgical Implants — Recombinant Collagen and Surgical Implants — Silk Fibroin — represent the first international standards ever established for bio-based materials in the surgical implant field, filling a critical gap in global medical device regulation, according to CCTV News.
A Strategic Shift from Follower to Leader
The approval marks a significant transition for China, which has long participated in international standardization efforts but rarely led them in the biomedical materials sector. Both standards will be spearheaded by Chinese experts serving as project leaders, with the United States, Germany, France, and other nations participating in the standard-setting process.
“Currently, China’s bio-based material technology strength and its application level in the medical device field have ranked among the world’s forefront,” said Han Qianqian, Director of the Medical Device Testing Institute at the China National Institutes for Food and Drug Control. “The successful project initiation of these two bio-based material international standards marks China’s transition from participation in individual standards to systematic leadership.”
What the Standards Cover
Recombinant collagen is produced through genetic engineering, inserting human collagen gene sequences into host cells such as bacteria or yeast, which then ferment and synthesize proteins structurally similar to human collagen. Silk fibroin is a natural high-molecular-weight fibrous protein extracted from silk. Both materials can be used in orthopedic, cardiovascular, and medical aesthetics applications, including drug carriers, absorbable implants, and wound dressings.
Han explained that the two standards establish comprehensive quality evaluation and quality control requirements for both materials as surgical implant substances. They propose a complete quality control indicator system covering production process control, final product specifications, and detailed testing methods.
Advantages Over Traditional Materials
Compared with conventional surgical implant materials, both recombinant collagen and silk fibroin offer significant clinical advantages. They demonstrate good biocompatibility and strong affinity with human tissues and cells, with no obvious immune rejection or toxicity. They can reduce complications such as inflammatory reactions and material intolerance. Crucially, because these materials gradually degrade as tissue heals, patients do not require secondary surgery for implant removal, reducing both pain and medical burden.
Economic and Industrial Implications
The global medical implant market reached $220 billion in 2025, with demand for bio-based materials rising steadily. China’s recombinant collagen product market alone exceeded 380 billion RMB in 2023 and is projected to surpass 2,000 billion RMB by 2030, according to Frost & Sullivan data cited by Industrysourcing.cn.
Han noted that China’s leading role in formulating these international standards “will help the two biomaterial industries usher in comprehensive development opportunities, fully consolidate China’s leading position in these two industrial fields, and boost the expansion of domestic medical bio-based materials into overseas markets.”
China’s Growing Standardization Infrastructure
China has built an extensive medical device standardization framework over the past decade. The country now operates 40 medical device standardization technical committees, maintains over 2,100 active medical device standards, and has achieved a 93% alignment rate with international standards. China leads or participates in 24 medical device international standards — 19 led by China, with 8 already published and 11 in progress.
According to the National Standardization Administration, China submitted 505 international standard proposals to ISO and IEC in 2025 alone, a 15.83% increase from the previous year. The country has cumulatively led the development and publication of 1,183 ISO and IEC standards during the 14th Five-Year Plan period (2021–2025), an 88.1% increase over the previous five-year period.
Forward-Looking Strategy
The National Standardization Administration and National Medical Products Administration are now forward-deploying standards for emerging technologies, including brain-computer interface medical devices, medical robots, and new biomaterial medical devices. This sustained push suggests China is positioning itself not merely as a manufacturing hub for biomedical materials, but as a global architect of the rules governing their safety, quality, and trade.
What to Watch
With the US, Germany, and France participating in the standard development process, the international community appears to recognize China’s technical expertise in this domain. The standards are expected to be developed over the coming months and, once published, could reshape global trade in advanced biomaterials — particularly for Chinese manufacturers seeking smoother access to overseas markets. The broader question remains how these standards will interact with existing national frameworks and whether they will accelerate the global adoption of bio-based surgical implants.